Gemcitabine Combined With Cisplatin

DRUG2 trials

Sponsors

Fudan University, Phanes Therapeutics

Conditions

Biliary Tract Cancer (BTC)Colorectal CancerGastric or Gastroesophageal Junction AdenocarcinomaNon Small Cell Lung CancerPancreatic Ductal Adenocarcinoma

Phase 1

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

RecruitingNCT05482893

Phanes TherapeuticsGastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC) +1

Start: 2023-03-15End: 2028-04-01Target: 350Updated: 2026-09-28

Phase 2

ABX Combined With Cisplatin Compared With Gemcitabine Combined With Cisplatin in NSCLC

CompletedNCT01810367

Fudan UniversityNon Small Cell Lung Cancer

Start: 2011-12-31End: 2015-12-31Updated: 2016-02-23

Related Papers

Spevatamig (PT886), a claudin 18.2 (CLDN18.2)/CD47 bispecific antibody, in combination with gemcitabine plus nab-paclitaxel (GnP) in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC).

Journal of Clinical Oncology2026-05-27

Phase 1/2 study of spevatamig (PT886) in combination with gemcitabine plus nab-paclitaxel (GnP) in frontline (1L) treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC).

Journal of Clinical Oncology2026-01-10